Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • News & Views
  • Published:

Psoriatic arthritis

Real-world data provide insights into PsA treatment patterns

Nature Reviews Rheumatology volume 19, pages 466–467 (2023)Cite this article

Subjects

Among the wide range of drugs now available for the treatment of psoriatic arthritis, the best option for an individual patient remains unclear. Emerging real-world evidence from several Nordic registries suggests that differences exist in the response rates to different classes of biologic and targeted synthetic DMARDs in psoriatic arthritis.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  1. McGonagle, D. G., McInnes, I. B., Kirkham, B. W., Sherlock, J. & Moots, R. The role of IL-17A in axial spondyloarthritis and psoriatic arthritis: recent advances and controversies. Ann. Rheum. Dis. 78, 1167–1178 (2019).

    Article  CAS  PubMed  Google Scholar 

  2. Harrison, S. R. & Marzo-Ortega, H. Have therapeutics enhanced our knowledge of axial spondyloarthritis? Curr. Rheumatol. Rep. 25, 56–67 (2023).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  3. Glintborg, B. et al. Uptake and effectiveness of newer biologic and targeted synthetic disease-modifying antirheumatic drugs in psoriatic arthritis: results from five Nordic biologics registries. Ann. Rheum. Dis. https://doi.org/10.1136/ard-2022-223650 (2023).

    Article  PubMed  Google Scholar 

  4. Ruyssen-Witrand, A. et al. Efficacy and safety of biologics in psoriatic arthritis: a systematic literature review and network meta-analysis. RMD Open 6, e001117 (2020).

    Article  PubMed  PubMed Central  Google Scholar 

  5. Lorenzin, M. et al. Predictive factors for switching in patients with psoriatic arthritis undergoing anti-TNFα, anti-IL12/23, or anti-IL17 drugs: a 15-year monocentric real-life study. Clin. Rheumatol. 40, 4569–4580 (2021).

    Article  PubMed  PubMed Central  Google Scholar 

  6. Fegerli, K. M. et al. Long-term persistence of TNF-inhibitor treatment in patients with psoriatic arthritis. Data from the British Society for Rheumatology Biologics Register. RMD Open 4, e000596 (2018).

    Article  Google Scholar 

  7. Coates, L. C. et al. Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA): updated treatment recommendations for psoriatic arthritis 2021. Nat. Rev. Rheumatol. 8, 465–479 (2022).

    Article  Google Scholar 

  8. Pouw, J., Leijten, E., Radstake, T. & Boes, M. Emerging molecular biomarkers for predicting therapy response in psoriatic arthritis: A review of literature. Clin. Immunol. 211, 108318 (2020).

    Article  CAS  PubMed  Google Scholar 

  9. Perrotta, F. M., Scriffignano, S., Ciccia, F. & Lubrano, E. Clinical characteristics of potential “difficult-to-treat” patients with psoriatic arthritis: a retrospective analysis of a longitudinal cohort. Rheumatol. Ther. 4, 1193–1201 (2022).

    Article  Google Scholar 

  10. Nagy, G. et al. EULAR definition difficult-to-treat rheumatoid arthritis. Ann. Rheum. Dis. 80, 31–35 (2021).

    Article  PubMed  Google Scholar 

Download references

Acknowledgements

H.M.-O. is supported by the National Institute for Health Research (NIHR) Leeds Biomedical Research Centre. The views expressed are those of the authors and not necessarily those of the UK National Health Service, the NIHR, or the UK Department of Health.

Author information

Authors and Affiliations

  1. NIHR Leeds Biomedical Research Centre, Leeds Teaching Hospitals NHS Trust, Leeds, UK

    Helena Marzo-Ortega & Stephanie R. Harrison

  2. Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, UK

    Helena Marzo-Ortega & Stephanie R. Harrison

Authors
  1. Helena Marzo-Ortega
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Stephanie R. Harrison
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Helena Marzo-Ortega.

Ethics declarations

Competing interests

H.M.-O. declares that she has received grants from Janssen, Novartis, Pfizer and UCB, and honoraria or consultancy fees from Abbvie, Biogen, Eli-Lilly, Janssen, Moonlake, Novartis, Pfizer, Takeda and UCB. S.R.H. declares no competing interests.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Marzo-Ortega, H., Harrison, S.R. Real-world data provide insights into PsA treatment patterns. Nat Rev Rheumatol 19, 466–467 (2023). https://doi.org/10.1038/s41584-023-00965-x

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41584-023-00965-x

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing